BioCentury
ARTICLE | Distillery Therapeutics

Neurology

March 28, 2017 3:53 PM UTC

Cell culture and mouse studies suggest promoting LPPR1 expression or inhibiting LPAR1 could help treat SCI. In primary mouse cortical neurons subjected to scrape injury, overexpression of LPPR1 increased regeneration of axons compared with normal expression. In a mouse model of SCI, intracortical infusion of the LPAR1 antagonist AM095 or overexpression of LPPR1 in corticospinal motor neurons increased corticospinal tract axon density in the spinal ventral horn compared with vehicle or normal LPPR1 expression. Also in the model, intracortical infusion of AM095 increased motor function compared with vehicle. Next steps could include identifying compounds that promote LPPR1 expression.

Bristol-Myers Squibb Co. has AM095 in preclinical testing to treat scleroderma...